Silver Book Fact

There are 23 medicines in development for stroke, the third leading cause of death after heart disease and cancer.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • In 2005, approximately 469,000 coronary artery bypass procedures were performed on 261,000 patients in the U.S.  
  • There are currently 312 medicines in development for heart disease and stroke.  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Every additional dollar spent on the routine use of beta-blockers (versus under-use) in acute heart attack patients has produced health gains valued as high as $38.44.